GlobeNewswire PharmaOriginal article
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
ConferenceREYOBIQCNSidePositive
AI Analysis
Summary
Cerenome presented data at the 2026 SNO/ASCO CNS Metastases Conference demonstrating REYOBIQ's CSF distribution and safety profile, and CNSide's potential to reduce monthly leptomeningeal metastases treatment costs by up to 47%.
Outcome Details
REYOBIQ CSF distribution and safety data presented; CNSide shown to potentially reduce monthly LM treatment costs by up to 47%
Importance:5/10
Sentiment:
0.60
CNS metastasesdiagnosticstherapeuticscost reductionconference presentation
Read the original article
Published by GlobeNewswire Pharma on August 20, 2026 11:30 AM